Literature DB >> 1448266

Labor induction in women at term with mifepristone (RU 486): a double-blind, randomized, placebo-controlled study.

R Frydman1, C Lelaidier, C Baton-Saint-Mleux, H Fernandez, M Vial, P Bourget.   

Abstract

OBJECTIVE: To determine the efficacy and safety of mifepristone as an induction agent for the initiation of labor or as a cervical ripening agent in women at term.
METHODS: Our study group contained 120 women at term (after 37.5 weeks' amenorrhea) who had clear clinical indications for labor induction. They were randomized to receive either 200 mg of mifepristone or placebo on days 1 and 2 of a 4-day observation period, with labor induction planned for day 4. Eight patients, three treated with mifepristone and five receiving placebo, had to be excluded from the survey because they required cesareans for medical reasons (fetal distress or maternal complications) less than 12 hours after taking the first tablet.
RESULTS: Forty-one subjects entered spontaneous labor, 31 treated with mifepristone and ten in the control group (P < .001). Forty-five needed cervical maturation with prostaglandins on day 4, 13 of whom had received mifepristone and 32 of whom had been given placebo (P < .001). Thirteen women treated with mifepristone and 13 who had taken placebo had mature cervices sufficient for classic labor induction with oxytocin and amniotomy. Patients who delivered vaginally needed a much lower amount of oxytocin when mifepristone had been given, and the mean time interval between day 1 of the survey and the onset of labor was also significantly shorter in this group.
CONCLUSION: Although more studies are needed, we have found mifepristone to be a safe, efficient, and suitable induction agent for initiation of labor in women at term.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1448266

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  22 in total

1.  Cervical ripening in the third trimester of pregnancy with intravaginal misoprostol: a double-blind, randomized, placebo-controlled study.

Authors:  Z Wang; W Li; W Ouyang; Y Ding; F Wang; L Xu; X Su
Journal:  J Tongji Med Univ       Date:  1998

Review 2.  Proven and potential clinical applications of mifpristone (RU486).

Authors:  Irving M Spitz
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

3.  Clinical pharmacokinetics of mifepristone.

Authors:  O Heikinheimo
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 4.  Progesterone treatment to prevent preterm birth.

Authors:  Paul J Meis; Alicia Aleman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Characterization of the myometrial transcriptome and biological pathways of spontaneous human labor at term.

Authors:  Pooja Mittal; Roberto Romero; Adi L Tarca; Juan Gonzalez; Sorin Draghici; Yi Xu; Zhong Dong; Chia-Ling Nhan-Chang; Tinnakorn Chaiworapongsa; Stephen Lye; Juan Pedro Kusanovic; Leonard Lipovich; Shali Mazaki-Tovi; Sonia S Hassan; Sam Mesiano; Chong Jai Kim
Journal:  J Perinat Med       Date:  2010-07-14       Impact factor: 1.901

6.  Revisiting reproduction: Prematurity and the puzzle of progesterone resistance.

Authors:  Yasushi Hirota; Jeeyeon Cha; Sudhansu K Dey
Journal:  Nat Med       Date:  2010-05       Impact factor: 53.440

Review 7.  Different methods for the induction of labour in outpatient settings.

Authors:  Therese Dowswell; Anthony J Kelly; Stefania Livio; Jane E Norman; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

Review 8.  Use of labour induction and risk of cesarean delivery: a systematic review and meta-analysis.

Authors:  Ekaterina Mishanina; Ewelina Rogozinska; Tej Thatthi; Rehan Uddin-Khan; Khalid S Khan; Catherine Meads
Journal:  CMAJ       Date:  2014-04-28       Impact factor: 8.262

Review 9.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

Review 10.  Minireview: fetal-maternal hormonal signaling in pregnancy and labor.

Authors:  Carole R Mendelson
Journal:  Mol Endocrinol       Date:  2009-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.